1-Methylpiperidin-4-amine dihydrochloride | 120088-53-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methylpiperidin-4-amine dihydrochloride
• 英文别名: 1-methylpiperidin-4-amine;dihydrochloride
• CAS: 120088-53-1
• 化学式: C6H16Cl2N2
• 分子量: 187.11
• InChiKey: ILOBUZORFXDVEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.88
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-phenylbenzo[d]oxazole-4-carboxylic acid 、 1-Methylpiperidin-4-amine dihydrochloride 以This compound was obtained in 38% yield as a white solid的产率得到N-(1-methylpiperidin-4-yl)-2-phenylbenzoxazole-4-carboxamide
  参考文献：
  名称：

  Benzoxazole carboxamides for treating CINV and IBS-D

  摘要：

  公式I和II的化合物：被披露为5-HT3抑制剂。那些表现出中枢活性的化合物可用于治疗化疗诱导恶心和呕吐症（CINV）; 那些抑制外周受体的化合物可用于治疗腹泻型肠易激综合征（IBS-D）。

  公开号：

  US07307094B2

文献信息

• [EN] THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS OXY-PHÉNYL-ARYLES THÉRAPEUTIQUES ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009053694A1

  公开（公告）日：2009-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明总体涉及治疗化合物领域，更具体地涉及如本文所述的某些氧基苯基芳基化合物（以下简称OPA化合物），其中，抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物和组合物，在体内外抑制CHK2激酶功能，以及治疗由CHK2介导的疾病和状况，包括通过抑制CHK2激酶功能而改善的疾病和状况，等等，包括诸如癌症等增殖性疾病，可选地与另一剂联合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）针对微管的药剂；（e）电离辐射。
• [EN] 1- 2' (1, 4'-BIPERIDIN-1'-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS<br/>[FR] DERIVES DE 1- 2' (1, 4'-BIPERIDIN-1'-YL)-1- (PHENYL) ETHYL CYCLOHEXANOL UTILES COMME MODULATEURS DU RECAPTAGE DE MONOAMINE DANS LE TRAITEMENT DES SYMPTOMES VASOMOTEURS
  申请人：WYETH CORP

  公开号：WO2005037279A1

  公开（公告）日：2005-04-28

  The present invention is directed to substituted N-heterocycle derivatives of formula (I), compositions containing these derivatives, and their use in the manufacture of a medicament for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof wherein : A is phenyl, naphthyl, thiophenyl, pyridinyl, furanyl, benzofuranyl, isobenzofuranyl, xanthenyl, pyrrolyl, indolizinyl, isoindolyl, indolyl, or benzothiophenyl, where 1 to 3 carbon atoms of said A is optionally replaced with a nitrogen atom; U is N or O; W is H or OR8; the other substituents are defined in the claims.

  本发明涉及式（I）的取代N-杂环衍生物，含有这些衍生物的组合物，以及它们在制造用于预防和治疗由单胺再摄取改善的病况的药物中的应用，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病以及其中的组合，特别是从主要抑郁障碍、血管运动症状、压力和急迫性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合中选择的那些病况，其中：A是苯基、萘基、噻吩基、吡啶基、呋喃基、苯并呋喃基、异苯并呋喃基、黄色素基、吡咯基、吲哚啉基、异吲哚基、吲哚基或苯并噻吩基，其中所述A的1至3个碳原子可选择地被氮原子取代；U是N或O；W是H或OR8；其他取代基在权利要求中定义。
• [EN] SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DERIVES DE CYCLOALCANOYL ARYLE SUBSTITUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：WYETH CORP

  公开号：WO2005037809A1

  公开（公告）日：2005-04-28

  The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及取代芳基环烷酰衍生物，含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病况的方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及这些疾病的组合，尤其是从包括重性抑郁障碍、血管运动症状、压力和急迫性尿失禁、纤维肌痛、疼痛、糖尿病神经病变等病况中选出的那些病况。
• [EN] PROCESS FOR THE PREPARATION OF ENCENICLINE FROM 7-CHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID CHLORIDE AND (R)-QUINUCLIDIN-3-AMINE IN THE PRESENCE OF IMIDAZOLE<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'ENCENICLINE À PARTIR DE CHLORURE D'ACIDE 7-CHLORO-BENZO[B]THIOPHÈNE-2-CARBOXYLIQUE ET DE (R)-QUINUCLIDIN-3-AMINE EN PRÉSENCE D'IMIDAZOLE
  申请人：SANDOZ AG

  公开号：WO2017060287A1

  公开（公告）日：2017-04-13

  The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiary amine group is comprised in a non-aromatic heterocycle and wherein the amide bond forms selectively with the primary amine group, comprising the step of reacting the carboxylic acid chloride with an organic molecule comprising both the primary amine group and the tertiary amine group, in the presence of imidazole. This is particularly useful in the preparation of amides from quinuclidin-3-amine, such as for the preparation of encenicline ((R) -7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide) from 7-chloro-benzo[b]thiophene-2-carboxylic acid chloride and (R)- quinuclidin-3-amine in the presence of imidazole. Encenicline is a nicotinic acetylcholine receptor agonist useful as a neuromodulator for the treatment of e.g. cognitive impairment, schizophrenia and Alzheimer's disease.

  本发明涉及一种从羧酸氯化物和同时含有一次胺基和三次胺基的有机分子制备酰胺的方法，其中三次胺基的氮原子包含在非芳香杂环中，且酰胺键选择性地与一次胺基形成，包括以下步骤：在咪唑存在下，将羧酸氯化物与同时含有一次胺基和三次胺基的有机分子反应。这在从喹诺啡-3-胺制备酰胺方面特别有用，例如从7-氯苯并[b]噻吩-2-羧酸氯化物和(R)-喹诺啡-3-胺在咪唑存在下制备encenicline ((R)-7-氯-N-(喹诺啡-3-基)苯并[b]噻吩-2-羧胺)。Encenicline是一种尼古丁乙酰胆碱受体激动剂，可作为神经调节剂用于治疗认知障碍、精神分裂症和阿尔茨海默病等疾病。
• Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
  申请人：Gregor Vlad E.

  公开号：US20080171769A1

  公开（公告）日：2008-07-17

  Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.

  提供的是化合物的结构式(I)：或其立体异构体、互变异构体、盐、水合物或前药，这些化合物调节酪氨酸激酶活性，包括这些化合物的组合物以及它们的使用方法。